Genentech Inc. said late Wednesday it has settled a long-running fight with MedImmune Inc. over one of the cornerstone patents of the biotech industry.
The patent, Cabilly II, covers certain manufacturing methods for monoclonal antibodies, a type of bioengineered protein that Genentech of South San Francisco, Calif., has turned into several lucrative medicines, including the cancer treatments Avastin and Herceptin. MedImmune filed its original complaint in April 2003.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
